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Purpose: The use of MR contrast agents allows accurate diagnosis by exerting an influence on the longi-
tudinal (T1) or transverse (T2) relaxation time of the surrounding tissue. In this study, we combined the
use of iron oxide (IO) particles and nonspecific extracellular gadolinium chelate (Gd) in order to further
improve the sensitivity and specificity of lesion detection.
Procedures: With a 7-Tesla scanner, pre-contrasted, IO-enhanced and dual contrast agent enhanced MRIs
were performed in phantom, normal animals, and animal models of lymph node tumor metastases and
orthotopic brain tumor. For the dual-contrast (DC) MRI, we focused on the evaluation of T2 weighted DC
MRI with IO administered first, then followed by the injection of a bolus of gadolinium diethylenetria-
mine pentaacetic acid (Gd-DTPA).
Results: Based on the C/N ratios and MRI relaxometry, the synergistic effect of coordinated administra-
tion of Gd-DTPA and IO was observed and confirmed in phantom, normal liver and tumor models. At
30 min after administration of Feridex, Gd-DTPA further decreased T2 relaxation in liver immediately
after the injection. Additional administration of Gd-DTPA also immediately increased the signal contrast
between tumor and brain parenchyma and maximized the C/N ratio to 4.12 ± 0.71. Dual contrast MRI
also enhanced the delineation of tumor borders and small lesions.
Conclusions: DC-MRI will be helpful to improve diagnostic accuracy and decrease the threshold size for
lesion detection.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Based on the interaction of protons with the surrounding mol-
ecules of tissues, magnetic resonance imaging (MRI) has been rec-
ognized as a powerful noninvasive diagnostic technique to
visualize the fine structure of a human body in high spatial resolu-
tion [1]. The use of MR contrast agents enables achievement of
clear images for accurate diagnosis, by exerting an influence on
the longitudinal (T1) or transverse (T2) relaxation time of the
surrounding tissue. Thermodynamically stable, water-soluble,
and highly paramagnetic Gd(III) complexes have demonstrated
high relaxivity and have therefore served as versatile T1 positive
contrast agents [2]. On the other hand, superparamagnetic iron
oxide (SPIO) NPs with superior magnetic properties have emerged
as a prevailing agent due to their strong T2 shortening effect [3,4].ll rights reserved.
ve, Suite 1C14, Bethesda, MD
, Bethesda, MD 20892-2281,
n.chen@nih.gov (X. Chen).Dextran coated iron oxide NPs (such as Ferridex) have been ap-
proved by the Food and Drug Administration (FDA) for clinical
use, particularly for detecting focal liver lesions [5–7].
Since the magnetite nanoparticles represent dark areas in MR
images, their negative contrast is often confused with a low-level
MR signal arising from adjacent tissues such as bone or vasculature
[8]. Furthermore, susceptibility artifacts can occur as a result of the
steep change of local magnetic field around iron oxide nanoparti-
cles, leading to the locally distorted anatomy of surrounding tissue
in MR image [9]. In order to improve the sensitivity and specificity
of lesion detection, several studies have described the combined
use of iron oxide particles and nonspecific extracellular gadolinium
chelate (Gd) [10–12]. Dual-contrast (DC) MR imaging involves the
administration of SPIO and gadopentetate dimeglumine contrast
agents in the same imaging session. By combining the enhance-
ment pattern of the nodules after gadolinium administration on
one hand and the tissue-specific information obtained after SPIO
administration on the other, this technique has been demonstrated
to improve the detection of hepatocellular carcinoma (HCC)
nodules [13,14].
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were administered together, the tumor-liver contrast-to-noise
(C/N) ratio magnitude reached a maximum at 12 min after drug
infusion [12]. DC-MRI with combined use of chondroitin sulfate
iron colloid (CSIC) and Gd-DTPA in patients with HCC also
demonstrated that DC-MRI was significantly better than Gd-DTPA
enhanced T1WI and CSIC enhanced T2WI in tumor detectability and
depicting tumor spread [15]. Sequential use of ferumoxide parti-
cles and nonspecific extracellular gadolinium chelate (Gd) for
evaluation of focal liver lesions on MRI revealed that Gd and
ferumoxide can be administered sequentially within one study ses-
sion without substantial loss of diagnostic information obtained on
sequences performed after administration of the second contrast
agent [11].
So far, most of DC-MRI studies were applied for lesion detection
within the liver. In order to elaborate the synergistic effect of SPIO
and gadolinium, in this study, we expanded the dual contrast en-
hanced MRI to lymph node metastasis and orthotopic brain tumor
models after a phantom study.2. Materials and methods
2.1. Contrast agents and phantom preparation
RGD conjugated IONPs were prepared according to the same
procedure reported previously [16]. For phantom preparation, dif-
ferent amount of free Ferumoxides suspension (Feridex I.V., Bayer
HealthCare Pharmaceuticals Inc., Wayne, NJ) was mixed with gad-
opentetate dimeglumine (Gd-DTPA Magnevist, Bayer Schering
Pharma AG, Berlin, Germany) in 200 ll 0.8% agarose. The concen-
tration gradient of Feridex ranges from 0 to 23.45 mg/ml and that
of Gd-DTPA ranges from 0 to 1.5625 lg/ml. In a container with a
diameter of 5 cm, six eppendorf tubes (0.8 cm in diameter) were
embedded in 0.8% agarose. For in vivo imaging, Gd-DTPA is diluted
in 0.9% NaCl to a concentration of 20 mM and injected in mice at a
dose of 0.02 mmol/kg. Feridex is also diluted in 0.9% NaCl and
injected in mice at a dose of 0.05 mmol Fe/kg.Fig. 1. MRI imaging of the phantoms. For phantom preparation, different amount of free
stand for the concentration gradient of Gd-DTPA ranging from 0 to 1.56 lg/ml (2-fold se
from 0 to 23.45 mg/ml (2-fold serial dilution). (A and B) T2-weighted MRI; (C and D) T12.2. Cell culture and animal model
Luciferase-expressing 4T1 murine breast cancer cells were
maintained at 37 C in a humidified atmosphere containing 5%
CO2 in Dulbecco’s Modification of Eagles Medium (DMEM) with
10% fetal bovine serum (FBS) [17]. The human glioblastoma cell
line U87MG was grown in DMEM medium supplemented with
10% FBS, 100 IU/ml penicillin, and 100 lg/ml streptomycin (Invit-
rogen), and in a humidified atmosphere containing 5% CO2 at 37 C.
All animal procedures were performed according to a protocol
approved by the National Institutes of Health Clinical Center Ani-
mal Care and Use Committee (NIH CC/ACUC). The lymph node
metastasis model was established in 4–6 week-old female BALB/c
mice by subcutaneous injection of 0.5  106 of 4T1-Luc cells to
the hock of the right leg of mice [17]. At day 14 to day 28 after cell
inoculation, tumor bearing mice (n = 5 each group) underwent bio-
luminescent imaging every three days to monitor tumor metasta-
sis to lymph nodes.
Orthotopic brain tumor model was established by stereotaxic
injection of 1  105 U87MG cells suspended in 5 ll phosphate-
buffered saline (PBS). The female athymic nude mouse (nu/nu) at
four to six weeks of age is placed in a stereotaxic jig made by Stoel-
ting (Wood Dale, IL). After the surgical area was cleaned and pre-
pared, an incision was made. The bregma was located to
determine the location of the craniotomy. The location of the
injection was 2 mm to the right and 0.5 mm rostral to the bregma.
The depth was 3 mm from the surface of the skull. Tumor cells
were allowed to engraft for 10 days, then MRI were performed
weekly to assess tumor growth.2.3. MRI
All experiments were performed on a 7 T MRI scanner (Bruker,
Germany) equipped with a single channel head coil for signal
reception.
For phantom acquisition, images were acquired with the
phantom parallel to the B0 direction using the following parame-Ferumoxides suspension was mixed with Gd-DTPA in 200 ll 0.8% agarose. G0 to G4
rial dilution) while F0 to F4 stand for the concentration gradient of Feridex ranging
-weighted MRI.
888 F. Zhang et al. / Biochemical and Biophysical Research Communications 425 (2012) 886–891ters: T1-weighted multislice gradient-echo images: TR/TE = 250/
4.5 ms, matrix = 256  256, FA = 30, 9 contiguous slices; T2-
weighted multislice spin-echo images: TR/TE = 2000/48 ms,
matrix = 256  256, 9 contiguous slices; T2-map: TR = 2000/
48 ms, matrix = 256  256, 1 slices, T2 relaxation measurements
with TE from 10 to 160 ms; T1 relaxation measurements were
acquired with TR of 120, 273, 454, 674, 957, 1354, 2021 and
5000 ms with a TE of 56 ms. All images had a 35 mm  35 mm field
of view. The T2 and T1 values of each phantom were calculated
using the fitting function provided by the manufacture software.
Different mouse data sets were acquired using a 4 cm receive-
only RF coil. Mice were anesthetized via inhalation of isoflurane
(1.5–2%) in O2. During the experiment, the temperature of the ani-
mal was maintained at 37.0 ± 0.5 C with the use of a circulating
warm water (37 C) blanket. The respiration rate was monitored
with an optical sensor of motion. All scan parameters were similar
to those of the phantom scan. All animals were imaged with T1-
and T2-weighted pulse sequences before administration of contrast
agents. Sequential administration of Feridex and Gd-DTPA was
performed for dual-contrast MRI. For lymph node imaging, a
catheter was inserted in a foot pad to allow administration of the
contrast agents. In one group of mice, Feridex was injected at
15 min after administration of Gd-DTPA. In another group, Gd-
DTPA was injected into the animals 30 min after administration
of iron oxide. Gd-DTPA and iron oxide contrast agents were admin-
istered at a dose of 0.2 mmol/kg and 0.05 mmol Fe/kg, respectively,
in a volume of 20 ll PBS through the foot pad.
For liver imaging, a catheter was inserted into a lateral tail vein
of mice. After catheter insertion, the animal was placed on a cus-
tom-made plastic cradle. Gd-DTPA was injected into the same ani-
mals 30 min after administration of iron oxide. Gd-DTPA and iron
oxide contrast agent is administered at a dose of 0.2 mmol/kg
and 0.05 mmol Fe/kg in a volume of 200 ll PBS respectively via

















Fig. 2. Dual-contrast T2-weighted MRI of normal livers. (A) T2-weighted MRI of a mous
administration (middle) and after administration of Gd-DTPA at 30 min after admin
administration of IO and Gd-DTPA. (C) Prussian blue staining of liver tissue.For brain tumor imaging, 0.2 mmol/kg of Gd-DTPA was injected
intravenously into the same animals 2 h after administration of IO-
RGD at a dose of 0.05 mmol Fe/kg. The images were acquired
immediately before, immediately after and 1 h after GD-DTPA
administration. The transverse relaxation rates and contrast-
to-noise (C/N) ratios were then measured.2.4. Image analysis
For phantom and animal liver study, MRI T2 relaxometry was
calculated. For lymph node tumor metastasis and brain tumor
models, quantitative analysis of the reference lesions was per-
formed by operator-defined regions of interest (ROIs). Signal inten-
sities of the normal lymph node, the reference lymph node lesion,
brain parenchyma, the reference brain tumor and the background
were measured in each animal for all sequences before and after
contrast administration. Then the C/N ratio was calculated with
following formula:C=Nlymph node ¼ ðSInomal lymph node
 SI tumor metastasisÞ=background noiseC=Nbrain tumor ¼ ðSItumor  SIbrain parenchymaÞ=background noiseThe C/N ratio is an effective parameter for quantitating MR
pulse sequence performance, as the absolute magnitude of C/N,
designated as [±C/N ratio], correlates with lesion detectability.
It follows from equation that negative C/N values indicate
relatively hypointense (dark) pathology. Values near zero denote
iso-intensity and poor lesion conspicuity [12,18].c
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Fig. 3. Dual-contrast MRI of lymph node metastases. (A and B) Unenhanced T1-weighted MRI with fast low-angle shot (FLASH) sequence. (C and D) Unenhanced T2-weighted
MRI with tuber fast spin echo sequence. (E) T1-weighted MRI immediately after administration of Gd-DTPA. (F) T2-weighted MRI at 30 min after iron oxide nanoparticles
administration. (G) T2-weighted dual contrast MRI with Gd-DTPA first then IO. (H) T2-weighted dual contrast MRI with IO first then Gd-DTPA. (I) Contrast-to-noise (C/N)
ratios calculated based on the signal intensity over the lymphatic tissue and metastatic tumor tissue. (J and K) Prussian blue staining of lymphatic tissue (J) and metastatic
tumor tissue (K) within the lymph node.
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A Student’s t-test was performed to determine if there was a
significant difference in C/N ratio. P-values of less than 0.05 were
considered statistically significant.3. Results
3.1. Phantom study
To validate the changes of relaxation rate of the mixed contrast
agent, we prepared phantom by mixing different concentrations of
Gd-DTPA and Feridex in 200 ll 0.8% agarose. Then T1- and T2-
weighted MR images were acquired and relaxation rates were
measured. As shown in Fig. 1, increased Gd-DTPA concentrations
without changing the iron oxide concentration can induce a nega-
tive signal enhancement on the T2-weighted images. This phenom-
enon is more prominent with low concentrations of iron oxide. At
the same time, iron oxide barely enhances the signal intensity even
at relatively high concentration range.3.2. Liver imaging
Feridex is a reticuloendothelial system (RES) specific intracellu-
lar superparamagnetic contrast agent and the particles are selec-
tively phagocytosed by hepatic Kupifer cells, decreasing signalintensity of normal liver but not the tumor. Consequently, most
of DC-MRI studies focused on lesion detection in the liver. As
shown in Fig. 2, Feridex enhanced the conspicuity of the whole li-
ver. At 30 min after administration of Feridex, Gd-DTPA further de-
creased T2 relaxation in the liver immediately after the injection. T2
relaxivity of DC-MRI is significantly higher than that of Feridex en-
hanced MRI (P < 0.05) (Fig. 2B). The iron oxide particle accumula-
tion inside the liver was confirmed by positive Prussian blue
staining (Fig. 2C).
3.3. Lymph node imaging
Local injection of contrast agent is the most common route for
lymph node imaging. Enlarged tumor draining lymph nodes are
detectable on both precontrast T1- and T2 weighted MRI. However,
virtually no contrast between tumor and healthy lymph node tis-
sue was identified. Gd-DTPA injection resulted in a profound signal
increase of surrounding lymph node tissue in contrast to the met-
astatic tumor. Administration of Feridex decreased signal intensity
in healthy lymph node tissue while tumor signal intensity did not
change. At 30 min after Feridex injection, administration of Gd-
DTPA increased tumor signal intensity while did not affect the sig-
nal loss in lymphatic tissue (Fig. 3). Consequently, the dual contrast
MRI further increased the C/N ratio to 7.89 ± 0.82, which is signif-
icantly higher than that of Feridex only (2.14 ± 1.36, P < 0.05).
Prussian blue staining revealed that iron oxide was mainly dis-
tributed in medullary sinuses in lymphatic tissue, which contrib-
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showed minimal iron oxide uptake, which corresponds to the re-
gion without signal reduction.
3.4. Brain tumor imaging
On precontrast T2 weighted MRI, orthotopic U87MG tumor pre-
sented higher signal intensity than peripheral brain parenchyma,
as shown in Fig. 4A. At 2 h after intravenous injection of RGD pep-
tide conjugated IO decreased tumor signal intensity in contrast to
brain parenchyma, indicating distribution of RGD-IO in the tumor
region. However, there is not significant decrease of the C/N ratio
compared with the precontrast MRI (P > 0.05). Additional adminis-
tration of Gd-DTPA immediately increased the signal contrast be-
tween tumor and brain parenchyma and maximized the C/N
ratio to 4.12 ± 0.71. At 1 h after Gd-DTPA injection, the signal
contrast was lost and the C/N ratio was restored.
More importantly, dual contrast MRI further enhanced the
delineation of tumor borders and small lesions. As is shown in
Fig. 4J, two satellite lesions were visualized clearly with dual con-
trast MRI, which were ambiguous on both precontrast MRI and IO-
RGD enhanced MRI (data no shown). HE staining confirmed the
existence of malignant lesions.
4. Discussion
Superparamagnetic iron oxide (SPIO) contrast agents have been
intensively applied in the identification and characterization of fo-
cal hepatic lesions [19,20]. Dynamic MRI following a bolus injec-
tion of paramagnetic Gd-DTPA is another widely used technique
to study liver cirrhosis and characterize HCC [21]. Dual contrast





































Fig. 4. Dual contrast MRI of othortopic brain tumors. (A) T2-weighted precontrast MRI. (B
MRI immediately after Gd-DTPA administration. (D) Dual contrast T2-weighted MRI im
calculated based on the signal intensity over the normal brain tissue and tumor tissue. (
weighted MRI for delineation and detection of small lesions.to improve the diagnostic accuracy of MRI in the study of focal
hepatic lesions [10,22]. They found that the small areas of arte-
rial-phase enhancement with Gd-DTPA that fail to take up SPIO
are always HCC. Consequently, the main advantage of DC-MRI for
HCC detection lies in that decreased contrast between tumor and
the liver parenchyma caused by Gd-DTPA administration is in-
creased by simultaneous use of iron oxide which reduces signal
intensity of the liver tissue surrounding the tumor.
As to the sequential use of ferumoxide particles and Gd-DTPA
for the evaluation of focal liver lesions on MRI, Semelka et al.
[11] studied the order of contrast administration and imaging ef-
fect of the first contrast agent on sequences acquired after the sec-
ond contrast agent. With ferumoxide first, a synergistic effect of
decreased signal intensity of normal liver background with ferum-
oxide particles and increased signal intensity of liver lesions with
Gd was identified on Gd-enhanced SGE images. This phenomenon
also has been identified with T1-weighted spin-echo images in rats
[12].
With phantom, we observed that increased Gd-DTPA concen-
trations without changing the iron oxide concentration can induce
a negative signal enhancement on the T2-weighted images, espe-
cially with low concentration of iron oxide (Fig. 1). The possible
explanation lies in that Gd3+ has seven unpaired electrons with
high paramagnetic susceptibility, and it can enhance the local field
gradient that was originally introduced by the superparamagnetic
nanoparticles. Thus, in this study, we focused on the evaluation of
T2 weighted dual contrast MRI with SPIO, expanding from normal
liver to tumor metastatic lymph nodes and brain tumor models.
There is no surprise to observe decreased signal intensity on T2-
weighted MRI after i.v. injection of SPIO (Fig. 2), due to the fact that
the heterogeneous distribution of superparamagnetic nanoparti-
cles introduces a big local field gradient that can be sensed by Gd3+.d
f
) T2-weighted MRI at 2 h after IO-RGD administration. (C) Dual contrast T2-weighted
mediately at 1 h after Gd-DTPA administration. (E) Contrast-to-noise (C/N) ratios
F) Prussian blue staining of brain tumor tissue. (G) Representative dual contrast T2-
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method that offers a high contrast and spatial resolution [23]. Inter-
stitial administration of lymphographic contrast media such as
SPIO [24,25] allows high accumulation in regional lymph nodes.
Consistent with previous studies [25], we also observed that
administration of Feridex decreased signal intensity in healthy
lymph node tissue while tumor signal intensity did not change.
Dual contrast MRI with Feridex injection first followed by adminis-
tration of Gd-DTPA further increased tumor signal intensity with-
out affecting the signal intensity in the lymphatic tissue (Fig. 3).
The synergistic effect may be beneficial to increase conspicuity of
tumor metastases in lymph nodes. After interstitial injection, SPIO
particles are taken up into highly permeable, thin walled and fenes-
trated lymphatic capillaries, and transported with the lymph fluid
to the lymph nodes and taken up by macrophages in the nodes
[26]. Metastatic tumors inside the lymph node showed minimal up-
take of SPIO as confirmed by Prussian blue staining. In contrast, Gd-
DTPA is more diffusible to the whole region of lymph nodes, which
may include the metastatic lesions [27]. By administering Gd-DTPA
first, no appreciable effect on the iron oxide-enhanced T2-weighted
images was observed (data not shown). We speculated that it may
be due to the much faster clearance rate of Gd-DTPA than SPIO.
The integrin avb3 receptor is upregulated on both tumor cells
and the endothelium, and it plays important roles in metastasis
and angiogenesis [28]. Various imaging methods have been tried
to visualize and quantify integrin expression in both preclinical
animal models and clinical settings [29,30]. We have visualized tu-
mor targeting of the integrin avb3 specific contrast agent, IONP-
RGD via MRI. With lower dose of IONP-RGD, we observed dropped
signal intensity in tumor region compared with brain parenchyma.
However, the signal contrast is not ideal (Fig. 4). A bolus injection
of Gd-DTPA significantly increased the lesion conspicuity and C/N
ratio. In particular, this method further delineated the border of
the malignant tumors, which is helpful in identifying small lesions.
At 1 h after Gd-DTPA injection, the signal enhancement and tumor
contrast was ambiguous due to the fast clearance of Gd-DTPA.
Besides the signal enhancement of Gd3+ to SPIO, the distinct
pharmacokinetic distribution of SPIO and Gd-DTPA further in-
creased C/N ratios with different administration routes in different
models. For example, in the case of tumor metastasis in lymph
nodes, interstitial injection of the contrast agents facilitated accu-
mulation of SPIO by macrophages in normal lymphatic tissues. On
the other hand, Gd-DTPA is more diffusive to tumor tissue and en-
hanced the signal intensity in metastatic tumors. In the case of
orthotopic brain tumor, normal brain parenchyma showed almost
no SPIO uptake comparing with tumor tissues. Administration of
Gd-DTPA further decreased signal intensity in tumors while in-
creased signal intensity of normal brain in T2 weighted images.
To conclude, the synergistic effect of dual contrast MRI is a result
of two contributions. One is from the high paramagnetic suscepti-
bility of Gd3+-enhanced local field gradient and the other is due to
the distinct pharmacokinetic distribution of SPIO and Gd-DTPA.
This synergistic effect of coordinated administration of Gd-DTPA
and IO was observed and confirmed in phantom, normal liver and
tumor models. This strategy will be helpful to improve diagnostic
accuracy and decrease the threshold size for lesion detection.
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